article thumbnail

Contemporary approach to cardiogenic shock care: a state-of-the-art review

Frontiers in Cardiovascular Medicine

Cardiogenic shock (CS) is a time-sensitive and hemodynamically complex syndrome with a broad spectrum of etiologies and clinical presentations. Despite contemporary therapies, CS continues to maintain high morbidity and mortality ranging from 35 to 50%.

article thumbnail

Impella Pump Improves Survival in STEMI-Related Cardiogenic Shock

Med Page Today

(MedPage Today) -- ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than 350 patients receiving.

article thumbnail

Microaxial Flow Pump Effects in Infarct-Related Cardiogenic Shock

JAMA Cardiology

This substudy of the Danish-German (DanGer) Shock randomized clinical trial investigates if the use of a microaxial flow pump reduces the need for pharmacological support and what the effects are on hemodynamics and lactate clearance in patients with ST-elevation myocardial infarction–induced cardiogenic shock.

article thumbnail

National Cardiogenic Shock Initiative Study Results Show Significant Increase in Heart Attack Survival

DAIC

Henry Ford Health's National Cardiogenic Shock Initiative research team. Cardiogenic shock is a critical condition in which the heart is unable to pump enough blood to sustain the body’s needs, depriving vital organs of blood supply. This can cause those organs to eventually stop functioning. In the U.S.,

article thumbnail

DanGer Shock: Microaxial Flow Pump versus Standard Care in Infarct-Related Cardiogenic Shock

Cardiology Update

The post DanGer Shock: Microaxial Flow Pump versus Standard Care in Infarct-Related Cardiogenic Shock appeared first on Cardiology Update. For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram.

article thumbnail

Cardiogenic Shock

American College of Cardiology

The goal of the DanGer Shock trial was to compare the safety and efficacy of Impella CP on top of standard care compared with standard care alone among patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock.

article thumbnail

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

European Journal of Heart Failure

Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality.